info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Rhabdomyosarcoma Companies

Rhabdomyosarcoma is a rare and aggressive type of cancer that arises from skeletal muscle cells. Companies involved in addressing rhabdomyosarcoma play critical roles in developing treatments, conducting research, and providing supportive care for individuals affected by this cancer. 

Rhabdomyosarcoma Key Companies

Latest Rhabdomyosarcoma Companies Update



Pfizer Phase 2 trial evaluating PF-06945007 in combination with standard chemotherapy for recurrent rhabdomyosarcoma shows promising results, with higher progression-free survival rates compared to the control group.


Tarveda Therapeutics Phase 2 trial for ARV-111 demonstrates improved overall survival rates in patients with advanced rhabdomyosarcoma who have already received other treatments.


Boehringer Ingelheim International GmbH Phase 1/2 trial for BI 899554, a PARP inhibitor, reveals encouraging early activity in rhabdomyosarcoma patients, paving the way for further investigation.


List of Rhabdomyosarcoma Key Companies in the Market



  • Boehringer Ingelheim International GmbH

  • Pfizer Inc

  • Eli Lilly & Company

  • Novartis AG

  • Bristol Myers Squibb Company

  • TAIHO ONCOLOGY INC.

  • Oasmia

  • Bellicum Pharmaceuticals Inc.

  • CELGENE CORPORATION

  • Eisai Co. Ltd.

  • MacroGenics Inc.

  • Tarveda Therapeutics.

  • Exelixis Inc.

  • and Ipsen Pharma


Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.